Sacco S, Bendtsen L, Ashina M, Reuter U, Terwindt G, Mitsikostas DD et al (2019) European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. J Headache Pain 20(1):6
Article
PubMed
PubMed Central
Google Scholar
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339:b2535
Article
PubMed
PubMed Central
Google Scholar
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372:n71
Article
PubMed
PubMed Central
Google Scholar
The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) system. Available from: http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. Accessed 15 Feb 2022.
Guyatt GH, Oxman AD, Vist G, Kunz R, Brozek J, Alonso-Coello P et al (2011) GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). J Clin Epidemiol 64(4):407–415
Article
PubMed
Google Scholar
Team RC (2020) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna Available from: https://www.R-project.org/
Google Scholar
Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026–1037
Article
PubMed
Google Scholar
Mulleners WM, Kim BK, Lainez MJA, Lanteri-Minet M, Pozo-Rosich P, Wang S et al (2020) Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol 19(10):814–825
Article
CAS
PubMed
Google Scholar
Skljarevski V, Matharu M, Millen BA, Ossipov MH, Kim BK, Yang JY (2018) Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 phase 3 randomized controlled clinical trial. Cephalalgia 38(8):1442–1454
Article
PubMed
Google Scholar
Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080–1088
Article
PubMed
PubMed Central
Google Scholar
Ferrari MD, Diener HC, Ning X, Galic M, Cohen JM, Yang R et al (2019) Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. Lancet 394(10203):1030–1040
Article
CAS
PubMed
Google Scholar
Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of Fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999–2008
Article
CAS
PubMed
Google Scholar
Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113–2122
Article
CAS
PubMed
Google Scholar
Reuter U, Ehrlich M, Gendolla A, Heinze A, Klatt J, Wen S et al (2022) Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial. Cephalalgia 42(2):108–118
Article
PubMed
Google Scholar
Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280–2287
Article
CAS
PubMed
Google Scholar
Sun H, Dodick DW, Silberstein S, Goadsby PJ, Reuter U, Ashina M et al (2016) Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol 15(4):382–390
Article
CAS
PubMed
Google Scholar
Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener HC et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1091–1100
Article
CAS
PubMed
Google Scholar
Bigal ME, Dodick DW, Rapoport AM, Silberstein SD, Ma Y, Yang R et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1081–1090
Article
CAS
PubMed
Google Scholar
Tepper S, Ashina M, Reuter U, Brandes JL, Dolezil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425–434
Article
CAS
PubMed
Google Scholar
Dodick DW, Lipton RB, Silberstein S, Goadsby PJ, Biondi D, Hirman J et al (2019) Eptinezumab for prevention of chronic migraine: a randomized phase 2b clinical trial. Cephalalgia 39(9):1075–1085
Article
PubMed
Google Scholar
Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241–254
Article
PubMed
PubMed Central
Google Scholar
Lipton RB, Goadsby PJ, Smith J, Schaeffler BA, Biondi DM, Hirman J et al (2020) Efficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2. Neurology 94(13):e1365–e1377
Article
CAS
PubMed
PubMed Central
Google Scholar
Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211–e2221
Article
CAS
PubMed
PubMed Central
Google Scholar
Goadsby PJ, Reuter U, Hallstrom Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of erenumab for episodic migraine. N Engl J Med 377(22):2123–2132
Article
CAS
PubMed
Google Scholar
Sakai F, Takeshima T, Tatsuoka Y, Hirata K, Lenz R, Wang Y et al (2019) A randomized phase 2 study of erenumab for the prevention of episodic migraine in Japanese adults. Headache 59(10):1731–1742
Article
PubMed
PubMed Central
Google Scholar
Wang SJ, Roxas AA Jr, Saravia B, Kim BK, Chowdhury D, Riachi N et al (2021) Randomised, controlled trial of erenumab for the prevention of episodic migraine in patients from Asia, the Middle East, and Latin America: the EMPOwER study. Cephalalgia 41(13):1285–1297
Article
PubMed
PubMed Central
Google Scholar
Sakai F, Suzuki N, Kim BK, Igarashi H, Hirata K, Takeshima T et al (2021) Efficacy and safety of fremanezumab for chronic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1092–1101
Article
PubMed
PubMed Central
Google Scholar
Sakai F, Suzuki N, Kim BK, Tatsuoka Y, Imai N, Ning X et al (2021) Efficacy and safety of fremanezumab for episodic migraine prevention: multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in Japanese and Korean patients. Headache 61(7):1102–1111
Article
PubMed
PubMed Central
Google Scholar
Takeshima T, Sakai F, Hirata K, Imai N, Matsumori Y, Yoshida R et al (2021) Erenumab treatment for migraine prevention in Japanese patients: efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Headache 61(6):927–935
Article
PubMed
PubMed Central
Google Scholar
Skljarevski V, Oakes TM, Zhang Q, Ferguson MB, Martinez J, Camporeale A et al (2018) Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol 75(2):187–193
Article
PubMed
Google Scholar
Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, Pozo-Rosich P (2021) Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months. J Headache Pain 22(1):120
Article
CAS
PubMed
PubMed Central
Google Scholar
McAllister P, Lamerato L, Krasenbaum LJ, Cohen JM, Tangirala K, Thompson S et al (2021) Real-world impact of fremanezumab on migraine symptoms and resource utilization in the United States. J Headache Pain 22(1):156
Article
CAS
PubMed
PubMed Central
Google Scholar
Ornello R, Casalena A, Frattale I, Gabriele A, Affaitati G, Giamberardino MA et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):32
Article
CAS
PubMed
PubMed Central
Google Scholar
Straube A, Stude P, Gaul C, Schuh K, Koch M (2021) Real-world evidence data on the monoclonal antibody erenumab in migraine prevention: perspectives of treating physicians in Germany. J Headache Pain 22(1):133
Article
CAS
PubMed
PubMed Central
Google Scholar
Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P et al (2017) Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: a retrospective claims analysis. Cephalalgia 37(5):470–485
Article
PubMed
Google Scholar
Hepp Z, Dodick DW, Varon SF, Gillard P, Hansen RN, Devine EB (2015) Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia 35(6):478–488
Article
PubMed
Google Scholar
Vandervorst F, Van Deun L, Van Dycke A, Paemeleire K, Reuter U, Schoenen J et al (2021) CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs. J Headache Pain 22(1):128
Article
CAS
PubMed
PubMed Central
Google Scholar
Dapkute A, Vainauskiene J, Ryliskiene K (2022) Patient-reported outcomes of migraine treatment with erenumab: results from a national patient survey. Neurol Sci 43(5):3305–3312
Article
PubMed
Google Scholar
Ornello R, Baraldi C, Guerzoni S, Lambru G, Andreou AP, Raffaelli B et al (2022) Comparing the relative and absolute effect of erenumab: is a 50% response enough? Results from the ESTEEMen study. J Headache Pain 23(1):38
Article
CAS
PubMed
PubMed Central
Google Scholar
Detke HC, Millen BA, Zhang Q, Samaan K, Ailani J, Dodick DW et al (2020) Rapid onset of effect of galcanezumab for the prevention of episodic migraine: analysis of the EVOLVE studies. Headache 60(2):348–359
Article
PubMed
Google Scholar
Igarashi H, Shibata M, Ozeki A, Day KA, Matsumura T (2021) Early onset and maintenance effect of galcanezumab in Japanese patients with episodic migraine. J Pain Res 14:3555–3564
Article
CAS
PubMed
PubMed Central
Google Scholar
Schwedt T, Reuter U, Tepper S, Ashina M, Kudrow D, Broessner G et al (2018) Early onset of efficacy with erenumab in patients with episodic and chronic migraine. J Headache Pain 19(1):92
Article
PubMed
PubMed Central
CAS
Google Scholar
Schwedt TJ, Kuruppu DK, Dong Y, Standley K, Yunes-Medina L, Pearlman E (2021) Early onset of effect following galcanezumab treatment in patients with previous preventive medication failures. J Headache Pain 22(1):15
Article
CAS
PubMed
PubMed Central
Google Scholar
Takeshima T, Nakai M, Shibasaki Y, Ishida M, Kim BK, Ning X et al (2022) Early onset of efficacy with fremanezumab in patients with episodic and chronic migraine: subanalysis of two phase 2b/3 trials in Japanese and Korean patients. J Headache Pain 23(1):24
Article
CAS
PubMed
PubMed Central
Google Scholar
Winner PK, Spierings ELH, Yeung PP, Aycardi E, Blankenbiller T, Grozinski-Wolff M et al (2019) Early onset of efficacy with fremanezumab for the preventive treatment of chronic migraine. Headache 59(10):1743–1752
Article
PubMed
Google Scholar
Lambru G, Hill B, Murphy M, Tylova I, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):61
Article
CAS
PubMed
PubMed Central
Google Scholar
Russo A, Silvestro M, Scotto di Clemente F, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21(1):69
Article
CAS
PubMed
PubMed Central
Google Scholar
Goadsby PJ, Dodick DW, Martinez JM, Ferguson MB, Oakes TM, Zhang Q et al (2019) Onset of efficacy and duration of response of galcanezumab for the prevention of episodic migraine: a post-hoc analysis. J Neurol Neurosurg Psychiatry 90(8):939–944
Article
PubMed
Google Scholar
McAllister PJ, Turner I, Reuter U, Wang A, Scanlon J, Klatt J et al (2021) Timing and durability of response to erenumab in patients with episodic migraine. Headache 61(10):1553–1561
Article
PubMed
Google Scholar
Kuruppu DK, North JM, Kovacik AJ, Dong Y, Pearlman EM, Hutchinson SL (2021) Onset, maintenance, and cessation of effect of galcanezumab for prevention of migraine: a narrative review of three randomized placebo-controlled trials. Adv Ther 38(3):1614–1626
Article
CAS
PubMed
PubMed Central
Google Scholar
Tepper SJ, Lucas S, Ashina M, Schwedt TJ, Ailani J, Scanlon J et al (2021) Timing and durability of response to erenumab in patients with chronic migraine. Headache 61(8):1255–1263
Article
PubMed
PubMed Central
Google Scholar
Silberstein SD, Cohen JM, Seminerio MJ, Yang R, Ashina S, Katsarava Z (2020) The impact of fremanezumab on medication overuse in patients with chronic migraine: subgroup analysis of the HALO CM study. J Headache Pain 21(1):114
Article
CAS
PubMed
PubMed Central
Google Scholar
Dodick DW, Doty EG, Aurora SK, Ruff DD, Stauffer VL, Jedynak J et al (2021) Medication overuse in a subgroup analysis of phase 3 placebo-controlled studies of galcanezumab in the prevention of episodic and chronic migraine. Cephalalgia 41(3):340–352
Article
PubMed
Google Scholar
Diener HC, Marmura MJ, Tepper SJ, Cowan R, Starling AJ, Diamond ML et al (2021) Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: subgroup analysis of PROMISE-2. Headache 61(1):125–136
Article
PubMed
Google Scholar
Pijpers JA, Louter MA, de Bruin ME, van Zwet EW, Zitman FG, Ferrari MD et al (2016) Detoxification in medication-overuse headache, a retrospective controlled follow-up study: does care by a headache nurse lead to cure? Cephalalgia 36(2):122–130
Article
CAS
PubMed
Google Scholar
Ornello R, Casalena A, Frattale I, Caponnetto V, Gabriele A, Affaitati G et al (2020) Conversion from chronic to episodic migraine in patients treated with erenumab: real-life data from an Italian region. J Headache Pain 21(1):102
Article
CAS
PubMed
PubMed Central
Google Scholar
Baraldi C, Castro FL, Cainazzo MM, Pani L, Guerzoni S (2021) Predictors of response to erenumab after 12 months of treatment. Brain Behav 11(8):e2260
Article
PubMed
PubMed Central
Google Scholar
Cainazzo MM, Baraldi C, Ferrari A, Lo Castro F, Pani L, Guerzoni S (2021) Erenumab for the preventive treatment of chronic migraine complicated with medication overuse headache: an observational, retrospective, 12-month real-life study. Neurol Sci 42(10):4193–4202
Article
PubMed
Google Scholar
Pham A, Burch R (2020) A real-world comparison of erenumab and galcanezumab in a tertiary headache center. Headache 60:4–5
Google Scholar
Sacco S, Lampl C, Maassen van den Brink A, Caponnetto V, Braschinsky M, Ducros A et al (2021) Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. J Headache Pain 22(1):39
Article
PubMed
PubMed Central
Google Scholar
Al-Hassany L, Goadsby PJ, Danser AHJ, MaassenVanDenBrink A (2022) Calcitonin gene-related peptide-targeting drugs for migraine: how pharmacology might inform treatment decisions. Lancet Neurol 21(3):284–294
Article
CAS
PubMed
Google Scholar
Overeem LH, Peikert A, Hofacker MD, Kamm K, Ruscheweyh R, Gendolla A et al (2022) Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: a multi-center retrospective cohort study. Cephalalgia 42:291–301
Patier Ruiz I, Sanchez-Rubio Ferrandez J, Carcamo Fonfria A, Molina Garcia T (2022) Early experiences in switching between monoclonal antibodies in patients with nonresponsive migraine in Spain: a case series. Eur Neurol 85:132–135
Ziegeler C, May A (2020) Non-responders to treatment with antibodies to the CGRP-receptor May profit from a switch of antibody class. Headache 60(2):469–470
Article
PubMed
Google Scholar
Noseda R, Bedussi F, Gobbi C, Zecca C, Ceschi A (2021) Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: analysis of the WHO pharmacovigilance database. Cephalalgia 41(7):789–798
Article
PubMed
Google Scholar
Bussiere JL, Davies R, Dean C, Xu C, Kim KH, Vargas HM et al (2019) Nonclinical safety evaluation of erenumab, a CGRP receptor inhibitor for the prevention of migraine. Regul Toxicol Pharmacol 106:224–238
Article
CAS
PubMed
Google Scholar
Yadav S, Yadav YS, Goel MM, Singh U, Natu SM, Negi MP (2014) Calcitonin gene- and parathyroid hormone-related peptides in normotensive and preeclamptic pregnancies: a nested case-control study. Arch Gynecol Obstet 290(5):897–903
Article
CAS
PubMed
Google Scholar
Favoni V, Giani L, Al-Hassany L, Asioli GM, Butera C, de Boer I et al (2019) CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP? J Headache Pain 20(1):27
Article
PubMed
PubMed Central
Google Scholar
MaassenVanDenBrink A, Meijer J, Villalon CM, Ferrari MD (2016) Wiping out CGRP: potential cardiovascular risks. Trends Pharmacol Sci 37(9):779–788
Article
CAS
PubMed
Google Scholar
Russell FA, King R, Smillie SJ, Kodji X, Brain SD (2014) Calcitonin gene-related peptide: physiology and pathophysiology. Physiol Rev 94(4):1099–1142
Article
CAS
PubMed
PubMed Central
Google Scholar
Mulder IA, Li M, de Vries T, Qin T, Yanagisawa T, Sugimoto K et al (2020) Anti-migraine calcitonin gene-related peptide receptor antagonists worsen cerebral ischemic outcome in mice. Ann Neurol 88(4):771–784
Article
CAS
PubMed
PubMed Central
Google Scholar
Depre C, Antalik L, Starling A, Koren M, Eisele O, Lenz RA et al (2018) A randomized, double-blind, placebo-controlled study to evaluate the effect of erenumab on exercise time during a treadmill test in patients with stable angina. Headache 58(5):715–723
Article
PubMed
PubMed Central
Google Scholar
Maassen van den Brink A, Rubio-Beltran E, Duncker D, Villalon CM (2018) Is CGRP receptor blockade cardiovascularly safe? Appropriate studies are needed. Headache 58(8):1257–1258
Article
CAS
PubMed
Google Scholar
Ashina M, Goadsby PJ, Reuter U, Silberstein S, Dodick DW, Xue F et al (2021) Long-term efficacy and safety of erenumab in migraine prevention: results from a 5-year, open-label treatment phase of a randomized clinical trial. Eur J Neurol 28(5):1716–1725
Article
PubMed
PubMed Central
Google Scholar
Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C (2021) Hypertension: a new safety risk for patients treated with erenumab. Headache 61(1):202–208
Article
PubMed
Google Scholar
Breen ID, Brumfiel CM, Patel MH, Butterfield RJ, VanderPluym JH, Griffing L et al (2021) Evaluation of the safety of calcitonin gene-related peptide antagonists for migraine treatment among adults with Raynaud phenomenon. JAMA Netw Open 4(4):e217934
Article
PubMed
PubMed Central
Google Scholar
Evans RW (2019) Raynaud's phenomenon associated with calcitonin gene-related peptide monoclonal antibody antagonists. Headache 59(8):1360–1364
Article
PubMed
Google Scholar
Manickam AH, Buture A, Tomkins E, Ruttledge M (2021) Raynaud’s phenomenon secondary to erenumab in a patient with chronic migraine. Clin Case Rep 9(8):e04625
Article
PubMed
PubMed Central
Google Scholar
Haanes KA, Edvinsson L, Sams A (2020) Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies. J Headache Pain 21(1):26
Article
PubMed
PubMed Central
Google Scholar
Holzer P, Holzer-Petsche U (2021) Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related Peptide's motor-stimulating and prosecretory function in the intestine. Front Physiol 12:820006
Article
PubMed
Google Scholar
Frattale I, Ornello R, Pistoia F, Caponnetto V, Colangeli E, Sacco S (2021) Paralytic ileus after planned abdominal surgery in a patient on treatment with erenumab. Intern Emerg Med 16(1):227–228
Article
PubMed
Google Scholar